

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Holly PRENTICE

Appl. No.: 10/532,197 (U.S. National Phase of PCT/US2003/033433)

Int'l. Filing Date: October 22, 2003

For: High Expression Locus Vector Based on Ferritin Heavy Chain

Gene Locus

Confirmation No.: To be assigned

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 2159.0580001/EKS/ELE

Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO/SB/08A and Form PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. Copies of documents FP1 and NPL1-NPL13 are submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicant has listed publication dates on the attached Form PTO/SB/08A and Form PTO/SB/08B based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

- 2 -

Holly Prentice Appl. No. 10/532,197

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return copies of the enclosed Form PTO/SB/08A and Form PTO/SB/08B, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Eldora L. Ellison

Attorney for Applicant Registration No. 39,967

Date: October 18, 2005

1100 New York Avenue, N.W. Washington, D.C. 20005-3934

(202) 371-2600

442194_1.DOC

U.S. Patent and Tra duction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Equivalent of Form PTO/SB/08A (07-05) Approved for use through 07/31/2006. Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO Complete if Known 10/532,197 (U.S. National Phase of Application Number PCT/US2003/033433) INFORMATION DISCLOSURE Int'l Filing Date: October 22, 2003 Filing Date STATEMENT BY APPLICANT First Named Inventor Holly Prentice (Use as many sheets as necessary) Art Unit To Be Assigned **Examiner Name** To Be Assigned Sheet of Attorney Docket Number 2159.0580001/EKS/ELE

	U.S. PATENT DOCUMENTS								
Examiner Cite Initials No. 1		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,				
initials	No.	Number-Kind Code ^{2 (If Known)}	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear				
	<u> </u>								
			1						
				·					
			1						

		Fo	REIGN PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
		Country Code ³ Number ⁴ Kind Code ³ (if known)			Relevant Passages or Relevant Figures Appear	Té
/D.G./	FP1	WO 04/037982 A2	05/06/2004	Biogen, Inc. and Prentice		
						-
						—
						<u>L</u>

442248_1.DOC

Signature Considered Considered	Examiner Signature	/David Guzo/	Date Considered	03/29/2008
---------------------------------	-----------------------	--------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known		
	Application Number	10/532,197 (U.S. National Phase of PCT/US2003/033433)	
INFORMATION DISCLOSURE	Filing Date	Int'l Filing Date: October 22, 2003	
STATEMENT BY APPLICANT	First Named Inventor	Holly Prentice	
(Use as many sheets as necessary)	Art Unit	To Be Assigned	
	Examiner Name	To Be Assigned	
Sheet 1 of 2	Attorney Docket Number	2159.0580001/EKS/ELE	

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T²			
/D.G./	NPL1	Guo, JH., et al., "Expression and Loading of Recombinant Heavy and Light Chain Homopolymers of Rat Liver Ferritin," <i>Arch. Biochem. Biophys. 335</i> :197-204, Academic Press, Inc. (1996)				
/D.G./	NPL2	Hentze, M.W., et al., "Cloning, characterization, expression, and chromosomal localization of a human ferritin heavy-chain gene," <i>Proc. Natl. Acad. Sci. USA</i> 83:7226-7230, The National Academy of Sciences (1986)				
/D.G./	NPL3	Klausner, R.D., et al., "Regulating the Fate of mRNA: The Control of Cellular Iron Metabolism," Cell 72:19-28, Cell Press (1993)				
/D.G./	NPL4	Kwak, E.L., <i>et al.</i> , "Role for NF-κB in the Regulation of Ferritin H by Tumor Necrosis Factor-α," <i>J. Biol. Chem. 270</i> :15285-15293, The American Society for Biochemistry and Molecular Biology, Inc. (1995)				
/D.G./	NPL5	Marziali, G., et al., "Transcriptional Regulation of the Ferritin Heavy-Chain Gene: the Activity of the CCAAT Binding Factor NF-Y Is Modulated in Heme-Treated Friend Leukemia Cells and during Monocyte-to-Macrophage Differentiation," Mol. Cell. Biol. 17:1387-1395, American Society for Microbiology (1997)				
/D.G./	NPL6	NCBI Entrez, GenBank Report, Accession No. AY147930, Prentice, H.L., Entry Date September 2005				
/D.G./	NPL7	NCBI Entrez, GenBank Report, Accession No. M18051, Murray, M.T., et al., Entry Date September 2005				
/D.G./	NPL8	NCBI Entrez, GenBank Report, Accession No. M18052, Murray, M.T., et al., Entry Date September 2005				
/D.G./	NPL9	NCBI Entrez, GenBank Report, Accession No. M18053, Murray, M.T., et al., Entry Date September 2005				
/D.G./	NPL10	Shin, YM., et al., "Enhanced Iron Uptake of Saccharomyces cerevisiae by Heterologous Expression of a Tadpole Ferritin Gene," Appl. Environ. Microbiol. 67:1280-1283, American Society for Microbiology (March 2001)				

Examiner	/David Guzo/	Date	03/29/2008
Signature	/David dazo/	Considered	03/23/2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for i	orm 1449/P7	Ю		Complete if Known		
NIE ODA		DICC		Application Number	10/532,197 (U.S. National Phase of PCT/US2003/033433)	
			CLOSURE	Filing Date	Int'l Filing Date: October 22, 2003	
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Holly Prentice	
				Art Unit	To Be Assigned	
				Examiner Name	To Be Assigned	
Sheet	2	of	2	Attorney Docket Number	2159.0580001/EKS/ELE	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
/D.G./	NPL11	Thompson, J.D., et al., "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice," <i>Nucleic Acids Res.</i> 22:4673-4680, Oxford University Press (1994)	
/D.G./	NPL12	Urlaub, G., et al., "Effect of Gamma Rays at the Dihydrofolate Reductase Locus: Deletions and Inversions," Som. Cell. Mol. Genet. 12:555-566, Plenum Publishing Corporation (1986)	
/D.G./	NPL13	Wilson, C., et al., "Position Effects on Eukaryotic Gene Expression," Annu. Rev. Cell. Biol. 6:679-714, Annual Reviews Inc. (1990)	

442196_1.DOC

Examiner /David Guzo/	Date 03/29/2008 Considered	
-----------------------	----------------------------	--

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.